Table 2. Screening Adults for Lipid Disorders*
| Study details |
LRC (34) |
HHS(35) |
WOSCOPS(36) |
AFCAPS(37) |
| Year |
1984 |
1987 |
1995 |
1998 |
| Duration (yr) |
7.4 |
5 |
4.9 |
5.2 |
| Intervention (dose) |
Cholestyramine (24g
qd) |
Gemfibrozil (600 mg
bid) |
Pravastatin (40 mg
qd) |
Lovastatin (20-40 mg
qd) |
| Inclusion |
Men with TC >265a
and LDL 190b |
Healthy Finnish men
(civil service or industrial employees); non-HDL [c]
cholesterol>200 |
Men with "elevated
LDL cholesterol" |
Men and women with
average TC and below-average HDL |
| Age range for inclusion
(yr) |
35-59 |
40-55 |
45-64 |
Men, 45-73, Women,
>55 |
| Number of subjects,
intervention/control |
1906/1900 |
2051/2030 |
3302/3293 |
3304/3301 |
| Mean age (yr) |
48 |
47 |
55 |
58 |
| Male (%) |
100 |
100 |
100 |
85 |
| White (%) |
95.5 |
~100 |
~100 |
89 |
| Mean BMI[d]
(kg/m2) |
26.25 |
26.6 |
26 |
27.05 |
| Hypertension (%) |
0 |
15 |
15 |
22 |
| Mean TC start (mg/dL) |
291.5 |
288.9 |
272 |
221 |
| Mean LDL start (mg/dL) |
215.5 |
NR[e] |
192 |
150 |
| Mean HDL start (mg/dL) |
45 |
47 |
44 |
Men, 36; Women, 40 |
| Current smokers (%) |
38 |
36 |
44 |
12.5 |
| Angina (5) |
0 |
0 |
5 |
0 |
| Diabetes |
0 |
2.65 |
1 |
2.5 |
| ASA[f]
use (%) |
NR |
NR |
3 |
17 |
*LRC, Lipids Research Council; HHS, Helsinki Heart
Study; WOSCOPS, West of Scotland Coronary Prevention Study; AFCAPS, Air
Force/Texas Coronary Atherosclerosis Prevention.
[a] TC indicates total cholesterol.
[b] LDL indicates low-density lipoprotein.
[c] HDL indicates high-density lipoprotein.
[d] BMI indicates body-mass index.
[e] NR indicates not reported.
[f] ASA indicates acetylsalicylic acid (aspirin).
Return to Document
540 Gaither Road Rockville, MD 20850